Tapentadol Semisolid Aqueous Composition Preservative-Free Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations containing tapentadol for topical and local administration face challenges with stability and preservative-related side effects, as they are prone to chemical and physical degradation, and common preservatives can cause allergic reactions and other adverse effects.
Innovation Solution
A semisolid aqueous pharmaceutical composition of tapentadol with reduced or no preservatives, leveraging tapentadol's inherent preservative properties to achieve stability and antimicrobial effects, with specific concentration ranges and pH adjustments to maximize its preservative effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If common preservatives are added to aqueous pharmaceutical compositions containing tapentadol, then microbial contamination is prevented, but allergic reactions and other adverse effects occur
Solution Approach 1:
The patent removes common preservatives (parabens, benzyl alcohol, sorbic acid) from the formulation and extracts only the essential preservative function, which is achieved by optimizing tapentadol concentration to 0.1-10% w/v. This eliminates harmful preservative side effects while maintaining microbial protection through the drug substance itself at therapeutic concentrations.
Solution Approach 2:
The patent makes tapentadol serve dual functions: as the active analgesic ingredient and as the preservative agent. By maintaining tapentadol at therapeutic concentrations (0.1-10% w/v), the formulation achieves both pain relief and microbial protection without requiring separate preservative substances, thereby eliminating preservative-related adverse effects.
2Adaptability or versatility
If aqueous media are used for pharmaceutical compositions, then drug stability is reduced and chemical degradation occurs, but formulation flexibility and patient compliance improve
Solution Approach 1:
The patent optimizes critical parameters including pH (adjusted to tapentadol's stability range), tapentadol concentration (0.1-10% w/v), and ionic strength to enhance stability. These parameter adjustments prevent chemical degradation while maintaining the aqueous formulation's flexibility and patient compliance advantages.
Solution Approach 2:
The patent creates a composite aqueous formulation containing tapentadol with optimized concentration and pH, combining multiple components (tapentadol, pH adjusters, buffers) to achieve both stability and formulation flexibility. The composite nature allows the system to maintain drug stability while preserving the benefits of aqueous media.
3Reliability
If tapentadol concentration is increased to maximize preservative effect, then antimicrobial protection is enhanced, but cost and potential systemic side effects increase
Solution Approach 1:
The patent uses partial action by maintaining tapentadol at moderate concentrations (0.1-10% w/v) that are sufficient for both analgesic effect and preservative function. This avoids excessive tapentadol concentrations while achieving adequate antimicrobial protection through the synergistic effect of tapentadol's inherent preservative properties at therapeutic levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves extended shelf-life and in-use stability without common preservative-related side effects, ensuring effective antimicrobial protection and minimizing systemic exposure during topical administration.
Implementation Method 1
leveraging tapentadol's inherent preservative properties to achieve stability and antimicrobial effects
Implementation Method 2
The stability of the active ingredient in the final product is a primary concern to the formulator. In general, drug substances are less stable in aqueous media than solid dosage forms
Implementation Method 3
Oxidative labile drug substances or vitamins, essential oils, and almost all fats and oils can be oxidized by auto-oxidation
Data Source
Figure 1
AI summary
The invention relates to a semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.